Evaluation of mesenchymal stem cell migration after equine tendonitis therapy.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Mesenchymal stem cells (MSCs) have been used to treat equine tendonitis with promising results; however, little is known about the potential migration of these cells. To assess the possible migration of MSCs from an implantation site in the superficial digital flexor tendon (SDFT) to a lesion in the SDFT of the contralateral limb. In vivo experimental study. Adipose-derived MSCs were isolated from 4 healthy horses. Lesions were induced in the SDFTs of both forelimbs, followed by intralesional implantation of autologous adipose-derived MSCs labelled with nanocrystals into one of the limbs. Flow cytometry of the peripheral blood mononuclear cells and fluorescence microscopy of biopsies of the SDFT lesions were used to search for the labelled cells. Labelled cells were detected among the peripheral blood mononuclear cells in all animals, but labelled cells were present only in the SDFTs that were treated with the intralesional implants. Nanocrystals were a valuable in vivo marker of MSCs to be used for tendonitis treatment. Although migration of MSCs to the bloodstream was observed, it was not possible to identify the labelled cells in the untreated tendons.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.